Biotest AG BIOTEST PREF SHS
Biotest AG BIOTEST PREF SHS/ DE0005227235 /
0N70
|
08/11/2024 15:10:33
|
Chg.
-1.95
|
Volume |
Bid- |
Ask- |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
25.75EUR
|
-7.04%
|
100,000
Turnover: 2.58 mill. |
-Bid Size: - |
-Ask Size: - |
2.43 bill.EUR |
0.05% |
12.81 |
Business description
Biotest is a provider of plasma proteins and biotherapeutic drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies.
Management board & Supervisory board
| CEO |
| Peter Janssen |
| Management board |
| Ainhoa Mendizabal Zubiaga, Dr. Jörg Schüttrumpf, Dr. Michael Ramroth, Dr. Georg Floß |
| Supervisory board |
| Dr. Bernhard Ehmer, David Bell, Uta Kemmerich-Keil, Jürgen Heilmann, Dirk Schuck, Raimon Grifols Roura |
Company data
| Name: |
Biotest AG |
| Address: |
Landsteinerstraße 5,D-63303 Dreieich |
| Phone: |
+49-6103-801-0 |
| Fax: |
+49-6103-801-150 |
| E-mail: |
mail@biotest.de
|
| Internet: |
www.biotest.de |
| Industry: |
Healthcare |
| Sector: |
Medical Products |
| Sub sector: |
Advanced Medical Devices |
| End of financial year: |
31/12 |
| Free Float: |
- |
| IPO date: |
14/10/1987 |
